H Influenzae MeningitisSymptoms, Doctors, Treatments, Advances & More
Learn About H Influenzae Meningitis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Martin Antonio practices practicing medicine in Banjul, Gambia. Mr. Antonio is rated as an Elite expert by MediFind in the treatment of H Influenzae Meningitis. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Strep Throat, H Influenzae Meningitis, Bacterial Meningitis, and Meningitis.
ETSU Physicians & Associates- Pediatrics
Demetrio Macariola is a Pediatrics provider practicing medicine in Johnson City, Tennessee. Dr. Macariola is rated as an Advanced provider by MediFind in the treatment of H Influenzae Meningitis. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses H Influenzae Meningitis, Bacterial Meningitis, Herpes Simplex Encephalitis, and Lyme Disease. Dr. Macariola is board certified in American Board Of Pediatrics.
Shamez Ladhani practices practicing medicine in London, United Kingdom. Ladhani is rated as an Elite expert by MediFind in the treatment of H Influenzae Meningitis. They are also highly rated in 22 other conditions, according to our data. Their clinical expertise encompasses H Influenzae Meningitis, Strep Throat, Meningitis, Bacterial Meningitis, and Splenectomy.
Summary: This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design. Part One is divided into four stages based on age and vaccine dose levels. Part Two consists of the 2-month-old vaccine/placebo groups.
Summary: Fosfomycin is an antibiotic discovered since 1969. Disodium fosfomycin, for intravenous use (C3H5Na2O4P) is a bactericidal antibiotic, available in Italy since 2019 (AIFA approval). It works by blocking the enzyme UDP-N-acetylglucosamine enolpyruvil transferase, inhibiting the synthesis of peptidoglycan. It binds poorly to plasma proteins and is distributed very well in various tissues such as: ey...